




#17

CERTIFICATE OF VERIFICATION

I, Masaki Yano of c/o, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 540-0001 Japan, state that the attached document is a true and complete translation to the best of my knowledge of Japanese Patent Application No. 1998-347802 filed on November 20, 1998.

Dated this 16th day of April, 2003

Masaki Yano
Masaki Yano



THIS PAGE BLANK (USPTO)



PATENT OFFICE
JAPANESE GOVERNMENT

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application: November 20, 1998
Application Number: Patent Application No. 1998-347802
Applicant(s): FUSO PHARMACEUTICAL INDUSTRIES, LTD.

Commissioner,
Patent Office



THIS PAGE BLANK (USPTO)

[Document Name]	Application for Patent
[Docket No.]	163447
[Date of Application]	November 20, 1998
[Addressee]	Commissioner, Patent Office
[International Patent Classification]	C07K 2/00 C07K 14/435 C07K 7/00 C12N 15/00 C12N 15/11 C12N 15/63 A61K 48/00 C12N 9/00 G01N 33/48
[Title of Invention]	NOVEL SERINE PROTEASE BSSP6
[Number of Claim(s)]	35
[Inventor]	
[Address]	133, Minamisuzuhara 3-chome, Itami-shi, Hyogo
[Name]	Hidetoshi UEMURA
[Inventor]	
[Address]	603, Kopomutsu, 569-1, Tsutsui-cho, Yamatokoriyama-shi, Nara
[Name]	Akira OKUI
[Inventor]	
[Address]	786-2, Jinenda, Hannan-shi, Osaka
[Name]	Katsuya KOMINAMI
[Inventor]	
[Address]	285-79, Shingoryoguchi-cho, Teramachinishi-iru, Kuramaguchi-dori, Kita-ku, Kyoto-shi, Kyoto
[Name]	Nozomi YAMAGUCHI
[Inventor]	
[Address]	202, Kitashirakawa-koporasu, 86, Kitashirakawanishi-machi, Sakyo-ku, Kyoto-shi,

THIS PAGE BLANK (USPTO)

Kyoto

[Name] Shinichi MITSUI

[Applicant]

[Identification No.] 000238201
[Address] 7-10, Doshomachi 1-chome, Chuo-ku,
Osaka-shi, Osaka
[Name] FUSO PHARMACEUTICAL INDUSTRIES,
LTD.

[Patent Attorney(s)]

[Identification No.] 100062144
[Name] Tamotsu AOYAMA

[Identification No.] 100081422
[Name] Mitsuo TANAKA

[Payment of Fees]

[Prepayment Book No.] 013262
[Amount to be paid] 21,000 yen

[Attached document]

[Item]	Specification	1
[Item]	drawing(s)	1
[Item]	Abstract	1
[Item]	Receipt of Microorganism Deposit	2

[General Power]

[Identification No.] 9700672

THIS PAGE BLANK (USPTO)



Document Name: Specification

Title of the Invention:

NOVEL SERINE PROTEASE BSSP6

Claims:

5 1. A protein having the amino acid sequence composed
of 229 amino acids represented by the 1st to 229th amino
acids of SEQ ID NO: 2; or a protein having an amino acid
sequence derived from the amino acid sequence represented
by the 1st to 229th amino acids of SEQ ID NO: 2 by deletion,
10 substitution or addition of one to several amino acids and
having the same property as that of the protein having the
amino acid sequence represented by the 1st to 229th amino
acids of SEQ ID NO: 2; or a modified derivative thereof.

 2. A nucleotide sequence represented by the 272nd to
15 958th bases of SEQ ID NO: 1; a nucleotide sequence encoding
the amino acid sequence represented by the 1st to 229th
amino acids of SEQ ID NO: 2; or a nucleotide sequence
hybridizable with a nucleotide sequence which is
complementary to the above nucleotide sequence under
20 stringent conditions and encoding a protein having the same
property as that of the protein having the amino acid
sequence represented by the 1st to 229th amino acids of SEQ
ID NO: 2.

 3. A protein having the amino acid sequence composed
25 of 229 amino acids represented by the 1st to 229th amino

acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 229th amino acids of SEQ ID NO: 4 by deletion, substitution or addition of one to several amino acids and
5 having the same property as that of the protein having the amino acid sequence represented by the 1st to 229th amino acids of SEQ ID NO: 4; or a modified derivative thereof.

4. A nucleotide sequence represented by the 244th to 930th bases of SEQ ID NO: 3; a nucleotide sequence encoding
10 the amino acid sequence represented by the 1st to 229th amino acids of SEQ ID NO: 4; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same
15 property as that of the protein having the amino acid sequence represented by the 1st to 229th amino acids of SEQ ID NO: 4.

5. A protein having the amino acid sequence composed of 282 amino acids represented by the -53rd to 229th amino
20 acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -53rd to 229th amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein
25 having the amino acid sequence represented by the -53rd to

229th amino acids of SEQ ID NO: 2; or a modified derivative thereof.

6. A nucleotide sequence represented by the 113th to 958th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -50th to 229th amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -50th to 229th amino acids of SEQ ID NO: 2.

7. A protein having the amino acid sequence composed of 250 amino acids represented by the -21st to 229th amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -21st to 229th amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -21st to 229th amino acids of SEQ ID NO: 2; or a modified derivative thereof.

8. A nucleotide sequence represented by the 209th to 958th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -21st to 229th

amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -21st to 229th amino acids of SEQ ID NO: 2.

9. A protein having the amino acid sequence composed of 249 amino acids represented by the -20th to 229th amino acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -20th to 229th amino acids of SEQ ID NO: 4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -20th to 229th amino acids of SEQ ID NO: 4; or a modified derivative thereof.

10. A nucleotide sequence represented by the 184th to 930th bases of SEQ ID NO: 3; a nucleotide sequence encoding the amino acid sequence represented by the -20th to 229th amino acids of SEQ ID NO: 4; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid

sequence represented by the -20th to 229th amino acids of SEQ ID NO: 4.

11. A protein having the amino acid sequence composed of 276 amino acids represented by the -47th to 229th amino acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -47th to 229th amino acids of SEQ ID NO: 4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -47th to 229th amino acids of SEQ ID NO: 4; or a modified derivative thereof.

12. A nucleotide sequence represented by the 103rd to 930th bases of SEQ ID NO: 3; a nucleotide sequence encoding the amino acid sequence represented by the -47th to 229th amino acids of SEQ ID NO: 4; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -47th to 229th amino acids of SEQ ID NO: 4.

13. A nucleotide sequence represented by SEQ ID NO: 1; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide

sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 1.

14. A nucleotide sequence represented by SEQ ID NO: 3;
5 or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 3.

10 15. A vector comprising the nucleotide sequence according to any one of claims 2, 4, 6, 8, 10 and 12-14.

16 Transformed cells having the nucleotide sequence according to any one of claims 2, 4, 6, 8, 10 and 12-14 in an expressible state.

15 17. A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to any one of claims 2, 6, 8 and 13, and collecting hBSSP6 produced.

20 18. A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to any one of claims 4, 10, 12 and 14, and collecting mBSSP6 produced.

19. The process according to claim 17 or 18, wherein the cells are *E. coli* cells, animal cells or insect cells.

25 20. A non-human transgenic animal whose expression

level of BSSP6 gene has been altered.

21. The non-human transgenic animal according to claim 20, wherein BSSP6 gene is cDNA, genomic DNA or synthetic DNA encoding BSSP6.

5 22. The non-human transgenic animal according to claim 20, wherein the expression level has been altered by mutating a gene expression regulatory site.

23. A knockout mouse whose BSSP6 gene function is deficient.

10 24. An antibody against the protein according to any one of claims 1, 3, 5, 7, 9 and 11, or a fragment thereof.

25. The antibody according to claim 24 which is a polyclonal antibody, a monoclonal antibody or a peptide antibody.

15 26. A process for producing a monoclonal antibody against the protein according to any one of claims 1, 3, 5, 7, 9 and 11, or a fragment thereof which comprises administering the protein according to any one of claims 1, 3, 5, 7, 9 and 11 or a fragment thereof to a warm-blooded
20 animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

25 27. A method for determining the protein according to

any one of claims 1, 3, 5, 7, 9 and 11, or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

5 28. A method for determining hBSSP6 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to any one of claims 1, 5 and 7, or a fragment thereof and a labeled antibody with hBSSP6 or a fragment
10 thereof in the specimen to detect a sandwich complex produced.

29. A method for determining hBSSP6 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein
15 according to any one of claims 1, 5 and 7, or a fragment thereof with labeled hBSSP6 and hBSSP6 or a fragment thereof in the specimen competitively to detect an amount of hBSSP6 or a fragment thereof in the specimen based on an amount of the labeled hBSSP6 reacted with the antibody.

20 30. The method according to any one of claims 27-29, wherein the specimen is a body fluid.

31. A diagnostic marker for diseases in tissues comprising the protein according to any one of claims 1, 3, 5, 7, 9 and 11, or a fragment thereof.

25 32. The marker according to claim 31 to be used for

diagnosis of Alzheimer's disease or epilepsy in brain.

33. The marker according to claim 31 to be used for diagnosis of cancer or inflammation of brain, medulla, prostate, placenta, heart, testicle or lung.

5 34. The marker according to claim 31 to be used for diagnosis of sterility in semen or sperms.

35. The marker according to claim 31 to be used for diagnosis of prostatic hypertrophy in prostate.

Detailed Description of the Invention:

10 [0001]

FIELD OF THE INVENTION

The present invention relates to isolated polynucleotides of human and mouse serine proteases (hereinafter referred to as "hBSSP6" and "mBSSP6",
15 respectively, and, in case no differentiation thereof from each other is needed, simply referred to as "BSSP6"), and their homologous forms, mature forms, precursors and polymorphic variants as well as a method for detecting thereof. Further, it relates to hBSSP6 and mBSSP6 proteins,
20 compositions containing hBSSP6 and mBSSP6 polynucleotides and proteins, as well as their production and use.

[0002]

PRIOR ART

In general, proteases are biosynthesized as inactive
25 precursors. They undergo limited hydrolysis in molecules

to convert into activated type proteases. In so far as enzymes are proteases, they have an activity for hydrolyzing a peptide bond, while their action modes are varied according to kinds of proteases. According to a particular kind of catalytic site, proteases are divided into serine proteases, cysteine proteases, aspartate proteases, metal proteases and the like. Proteases of each kind have a variety of properties, ranging from a protease having general digestive properties to a protease having various regulatory domains and strict substrate specificity, thereby specifically hydrolyzing only characteristic proteins.

[0003]

Further, proteins undergo various processing even after translation to produce active proteins. In many secretory proteins, a protein are first synthesized on the ribosome in cytoplasm as an inactive precursor (pro-form) which comprises an active protein bearing at the N-terminus thereof a peptide of about 15 to 60 amino acids responsible for secretion (secretory signal). This peptide region is concerned with the mechanism for passing through the cell membrane and is removed upon cleavage by a specific protease during the passage through the membrane, in almost all the cases, to produce the mature type protein. A secretory signal has a broad hydrophobic region comprising

hydrophobic amino acids in the middle of the sequence, and basic amino acid residues at a site close to the N-terminus. A secretory signal is a synonym of a signal peptide. In addition, in some proteins, a peptide moiety which
5 functions as a secretory signal is further attached to the N-terminus of the inactive precursor. Such a protein is called a prepro-protein (prepro-form).

[0004]

For example, trypsin is present as a prepro-form
10 immediately after translation into amino acids. After being secreted from cells, it is present as a pro-form and is converted into active trypsin in duodenum upon limited hydrolysis by enteropeptidase or by trypsin itself.

The optimal pH range of serine proteases is neutral to
15 weak alkaline and, in general, many of them have a molecular weight of about 30,000 or lower. All proteases of blood coagulation, fibrinolysis and complement systems having a large molecular weight belong to trypsin-like serine proteases. They have many regulator domains and
20 form a protease cascade which is of very importance to reactions in a living body.

[0005]

Recently, cDNAs and amino acid sequences of many novel proteases have been determined by PCR for consensus
25 sequences of serine proteases using oligonucleotide primers.

According to this method, novel proteases have been found by various researchers such as Yamamura et al. (Yamanura, Y et al., Biochem. Biophys. Res. Commun., 239, 386, 1997), Gschwend, et al. (Gschwend, T. P. et al., Mol. Cell. Neurosci., 9, 207, 1997), Chen et al. (Chen, Z-L, et al., J. Neurosci., 15, 5088, 1995) and others.

SEQ ID NO: 3 of JP 9-149790 A discloses neurosin as a novel serine protease. Neurosin has also been reported in Biochimica et Biophysica Acta, 1350, 11-14, 1997. By this, there is provided a method for mass production of neurosin using the serine protease gene and a method for screening specific inhibitors using the enzyme. In addition, the screening method has been shown to be useful for screening medicines for treating various diseases.

[0006]

PROBLEM TO BE SOLVED BY THE INVENTION

Under these circumstances, the present inventors have succeeded in cloning of cDNA encoding novel human and mouse serine proteases. The present inventors have shown that the mature type of the novel human serine protease (hBSSP6) is composed of 229 amino acids, the prostate type thereof is composed of 282 amino acids (the -53rd to 229th amino acids of SEQ ID NO: 2) and the brain type thereof is composed of 250 amino acids (the -21st to 229th amino acids of SEQ ID NO: 2). The placenta type thereof is considered

to be a larger protein started from methionine located at a more upstream region. Further, the present inventors have shown that the mature type of mutant type of hBSSP6 (hereinafter referred to as mutant hBSSP6) is composed of 254 amino acids (the 1st to 254 amino acids of SEQ ID NO: 6). The present inventors have shown that the mature type of the novel mouse serine protease (mBSSP6) is composed of 229 amino acids (the 1st to 229th amino acids of SEQ ID NO: 4), the brain type thereof is composed of 249 amino acids (the -20th to 229th amino acids of SEQ ID NO: 4) and the prostate type thereof is composed of 276 amino acids (the -47th to 229th amino acids of SEQ ID NO: 4). In addition, amino acid sequences of the mature type serine proteases contain consensus sequences having serine protease activity.

[0007]

In case of northern blotting analysis, the expression of hBSSP6 is observed in each part of brain, medulla, placenta, lung, heart, prostate, testicle, mucous membrane gland, etc., and the expression of mBSSP6 is observed in brain of 15-day fetus and testicle and prostate of 3-month-old mouse. In case of RT-PCR analysis, the expression of hBSSP6 is observed in hippocampus and prostate of the adults, and the expression of mBSSP6 is observed in brain of newborn to 12-day-old mice and in prostate of 4-month-old mouse. Then, the novel proteases of the present

invention are presumed to play various roles in brain, prostate, medulla, lung, placenta, heart, testicle and mucous membrane gland. For example, in brain, there is a possibility that they can be used for treatment and diagnosis of brain diseases such as Alzheimer's disease (AD), epilepsy, brain tumor and the like. Further, in other tissues, there is a possibility that they can be used for treatment and diagnosis of various diseases such as cancer, in particular, prostatic cancer, inflammation, sterility, prostate hypertrophy and the like. Furthermore, it is presumed they may have a certain influence on blood coagulation, fibrinolysis and complement systems. Moreover, an inhibitor of the novel protease of the present invention can be used for preventing or treating various diseases such as Alzheimer's disease, epilepsy, cancer and the like.

[0008]

Nowadays, in general, clinical diagnosis of Alzheimer's disease is conducted based on the diagnosis standard of DSM-IIIR and NINCDS-ADRDA (McKhann, G. et al., Neurology, 34. 939, 1994) or the diagnosis standard of DSM-IV (American Psychiatric Association; Diagnostic and statistical manuals of mental disorders, 4th ed., Washington DC, American Psychiatric Association, 1994). However, these standards are conditioned by decline of recognition functions which causes a severe disability in a

daily life or a social life. Then, it is pointed out that the diagnosis is less scientific objectivity because the diagnosis may be influenced by the level of an individual's social life and further the specialty and experience of a physician who diagnoses particular conditions. In addition, definite diagnosis of Alzheimer's disease is conducted by pathohistological analyses and, in this respect, substantial inconsistency between clinical diagnosis and autopsy diagnosis is pointed out.

10 [0009]

At present, image diagnosis is employed as a supplemental means in clinical diagnosis of Alzheimer's diagnosis and it is possible to analyze brain functions, for example, decline of metabolism and atrophy in specific sites such as hippocampus, parietal lobe of cerebral cortex and the like which are specific for Alzheimer's disease by PET and SPECT. However, to define Alzheimer's disease based on lowering of a blood flow from parietal lobe to temporal lobe is very dangerous. In addition, there is few report showing that MRS testicle useful for patients with dementia including those of Alzheimer's disease. Further, although CT-MRI image diagnosis is used, a lesion of white matter such as atrophy of brain, PVL or the like is not specific for Alzheimer type dementia. Since it has been reported that atrophy of brain proceeds as getting older,

15
20
25

the above observation is not necessarily found in Alzheimer type dementia. Furthermore, since an image obtained by MRI varies according to strength of a magnetic field, performance of an apparatus and imaging conditions, numerical data obtain in different facilities cannot be compared with each other except atrophic change. In addition, there is a limit to image measurement. Further, enlargement of ventricle can be recognized in vascular dementia cases and there are cases wherein atrophy of hippocampus is observed after ischemia of basilar artery.

[0010]

Under these circumstances, many researchers have requested to develop biological diagnosis markers as a means for providing better precision and objectivity for clinical diagnosis of Alzheimer's disease. At the same time, the following important roles in the future will be expected.

1) Objective judgment system of effect of medicaments for treating Alzheimer's disease.

2) Detection of Alzheimer's disease before a diagnosis standard is met, or disease conditions are manifested.

Further, data obtained in different facilities can be compared with each other by using the same diagnosis marker. Therefore, development of biological diagnosis markers is recognized to be a most important field among fields of

Alzheimer's disease studies and its future prospects will be expected. Approaches to development of biological diagnosis markers up to now are divided into that based on constitute components of characteristic pathological changes of Alzheimer's disease such as senile plaque and neurofibril change, and an approach based on other measures. Examples of the former include cerebrospinal fluid tau protein, A β and its precursor, β APP. Examples of the latter include mydriasis test with cholinergic drug, Apo E and other genes relating to Alzheimer's disease. However, no good results are obtained.

[0011]

The novel serine proteases of the present invention are also considered to play important role in cancer cells. The reason why extermination of cancer by surgical treatment or topical irradiation of radioactive ray is difficult is metastasis capability of cancer. For spread of solid tumor cells in a body, they should loosen their adhesion to original adjacent cells, followed by separating from an original tissue, passing through other tissues to reach blood vessel or lymph node, entering into the circulatory system through stratum basal and endothelial layer of the vessel, leave from the circulatory system at somewhere in the body, and surviving and proliferating in a new environment. While adhesion to adjacent epidermal

cells is lost when expression of cadherin which is an intercellular adhesive molecule of epithelium is stopped, to break through tissues is considered to depend on proteolytic enzymes which decompose an extracellular matrix.

5 [0012]

As enzymes which decompose the matrix, mainly, metal proteases (Rha, S. Y. et al., Breast Cancer Research Treatment, 43, 175, 1997) and serine proteases are known. They cooperate to decompose matrix protein such as collagen, 10 laminin and fibronectin. Among serine proteases known to be concerned in decomposition of the matrix, in particular, there is urokinase type plasminogen activator (U-PA). U-PA has a role as a trigger specific for a protein decomposition chain reaction. Its direct target is 15 plasminogen. It is present in blood abundantly and is a precursor of an inactive serine protease which accumulates in reconstructed sites of tissues such as injured sites and tumors as well as inflammatory sites. In addition, as proteases which are concerned in metastasis and 20 infiltration of cancers, for example, a tissue factor, lysosomal type hydrolase and collagenase have been known.

[0013]

At present, cancer is the top cause of death in Japan and more than 200,000 people are died per year. Then, 25 specific substances which can be used as markers for

diagnosis and therapy or prophylaxis of cancer are studied intensively. Such specific substances are referred to as tumor markers or tumor marker relating biomarkers. They are utilized in aid of diagnosis before treatment of cancer, for presuming carcinogenic organ and pathological tissue type, for monitoring effect of treatment, for finding recurrence early, for presuming prognosis, and the like. At present, tumor markers are essential in clinical analyses. Among them, alpha fetoprotein (AFP) which has high specificity to hepatocellular carcinoma and yolk sac tumor (Taketa K. et al., Tumour Biol., 9, 110, 1988), and carcinoembryonic antigen (CEA) are used worldwide. In the future, tumor markers will be required more and more, and it is desired to develop, for example, organ specific markers and tumor cell specific markers which are highly reliable serologic diagnosis of cancer. Up to now, humunglandular kallikrein (hK2) which is a serine protease expressed at human prostatic epithelial cells has been reported as a marker for prostatic cancer. And, hK2 has 78% homology with the sequence of prostatic specific antigen (PSA) and PSA is also used widely as a biochemical marker of prostatic cancer (Mikolajczyk, S. d. et al., Prostate, 34, 44, 1998; Pannek, J. et al., Oncology, 11, 1273, 1997; Chu, T. M. et al., Tumour Biology, 18, 123, 1997; Hsieh, M. et al., Cancer Res., 57, 2651, 1997).

Moreover, CYFRA (CYFRA 21-1) for measuring cytokeratin 19 fragment in serum is reported to be useful for lung cancer (Sugiyama, Y. et al., Japan J. Cancer Res., 85, 1178, 1994). Gastrin release peptide precursor (ProGRP) is reported to be useful as a tumor marker (Yamaguchi, K. et al., Japan, J. Cancer Res., 86, 698, 1995).

[0014]

Thus, the main object of the present invention is to provide a novel serine protease which can be used for treating or diagnosing various diseases such as Alzheimer's disease (AD), epilepsy, cancer, inflammation, sterility, prostate hypertrophy and the like in various tissues such as each part of brain, medulla, prostate, testicle, mucous membrane gland, placenta, heart, lung and the like, and can be used as an excellent marker instead of that presently used.

[0015]

MEANS FOR SOLVING THE PROBLEM

The 1st feature of the present invention is amino acid sequences of biological active mature serine proteases hBSSP6 and mBSSP6 and nucleotide sequences encoding the amino acid sequences.

That is, they are the amino acid sequence composed of 229 amino acids (the 1st to 229th amino acids) represented by SEQ ID NO: 2 (the mature type hBSSP6 (SEQ ID NO: 2)) and

a nucleotide sequence encoding the amino acid sequence (the 272nd to 958th bases of SEQ ID NO: 1). In addition, they include amino acid sequences substantially similar to SEQ ID NO: 2 and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of proteins having these amino acid sequences. An amino acid sequence substantially similar to a given amino acid sequence used herein means an amino acid sequence derived from the given amino acid sequence by modification such as substitution, deletion, addition and/or insertion of one to several amino acids with maintaining the same property as that of the protein having the given amino acid sequence. The modified derivative of the proteins includes, for example, phosphate adduct, sugar chain adduct, metal adduct (e.g., calcium adduct), the protein fused to another protein such as albumin etc., dimer of the protein, and the like.

[0016]

Further, they are the amino acid sequence composed of 229 amino acids (the 1st to 229th amino acids) or SEQ ID NO: 4 (the mature type mBSSP6 (SEQ ID NO: 4)) and a nucleotide sequence encoding the amino acid sequence (the 224th to 930th bases of SEQ ID NO: 3). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such

similar amino acid sequences. Further, they include modified derivatives of proteins having these amino acid sequences.

[0017]

5 Another feature of the present invention is an amino acid sequence composed of 282 amino acids (prostate type hBSSP6 (the -70th to 229th amino acids of SEQ ID NO: 2)) wherein 70 amino acids represented by the -50th to -1st amino acids of SEQ ID NO: 2 is added to the N-terminus side
10 of the mature type hBSSP6 amino acid sequence (SEQ ID NO: 2) and a nucleotide sequence encoding the amino acid sequence (the 113th to 958th bases of SEQ ID NO: 1). In addition, this feature includes amino acid sequences substantially similar to the amino acid sequence and
15 nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

20 Another feature of the present invention is an amino acid sequence composed of 250 amino acids (the brain type hBSSP6 (the -21st to 229th amino acids of SEQ ID NO: 2)) wherein 21 amino acids represented by the -21st to -1st amino acids of SEQ ID NO: 2 is added to the N-terminus side of the mature type hBSSP6 amino acid sequence (SEQ ID NO:
25 2) and a nucleotide sequence encoding the amino acid

sequence (the 209th to 958th bases of SEQ ID NO: 1). In addition, this feature includes amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

[0018]

Another feature of the present invention is an amino acid sequence composed of 249 amino acids (the brain type mBSSP6 (the -20th to 229th amino acids of SEQ ID NO: 4)) wherein 20 amino acids represented by the -21st to -1st amino acids of SEQ ID NO: 4 is added to the N-terminus side of the mature type mBSSP6 amino acid sequence (SEQ ID NO: 4) and a nucleotide sequence encoding the amino acid sequence (the 184th to 930th bases of SEQ ID NO: 1). In addition, this feature includes amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

Another feature of the present invention is an amino acid sequence composed of 276 amino acids (the prostate type mBSSP6 (the -47th to 229th amino acids of SEQ ID NO:

4)) wherein 47 amino acids represented by the -47th to -1st amino acids of SEQ ID NO: 4 is added to the N-terminus side of the mature type mBSSP6 amino acid sequence (SEQ ID NO: 4) and a nucleotide sequence encoding the amino acid sequence (the 103rd to 930th bases of SEQ ID NO: 3). In addition, this feature includes amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

Hereinafter, unless otherwise stated, the nucleotide sequence represented by each SEQ ID NO: includes the above-described various fragments thereof, and similar nucleotide sequences and their fragments. Likewise, the amino acid sequence represented by each SEQ ID NO: includes the above-described various fragments thereof, similar amino acid sequences and their fragments, and modified derivatives thereof. In addition, unless otherwise stated, BSSP6, hBSSP6, and mBSSP6 include proteins having the above-described respective amino acid sequences.

[0019]

PREFERRED EMBODIMENT OF THE INVENTION

The nucleotide sequences encoding hBSSP6 or mBSSP6 of the present invention can be obtained by preparing mRNAs

from cells expressing the protein and converting it into double stranded DNAs according to a conventional manner. For preparing mRNA, guanidine isothiocyanate-calcium chloride method (Chirwin, et al., Biochemistry, 18, 5294, 5 1979) or the like can be used. For preparing poly (A) + RNA from total RNAs, there can be used affinity chromatography using a carrier, for example, Sepharose, latex particles, etc., to which oligo (dT) is attached, and the like. The above-obtained RNA can be used as a template 10 and treated with reverse transcriptase by using, as a primer, oligo (dT) which is complementary to the poly (A) strand at the 3'-terminus, or a random primer, or a synthesized oligonucleotide corresponding to a part of the amino acid sequence of hBSSP6 or mBSSP6 to obtain a hybrid 15 mRNA strand comprising DNA complementary to the mRNA or cDNA. The double stranded DNA can be obtained by treating the above-obtained hybrid mRNA strand with *E. coli* RNase, *E. coli* DNA polymerase and *E. coli* DNA ligase to convert into a DNA strand.

20 [0020]

It is also possible to carry out cloning by RT-PCR method using primers synthesized on the basis of the nucleotide sequence of hBSSP6 or mBSSP6 gene and using hBSSP6 or mBSSP6 expressing cell poly (A) + RNA as a 25 template. Alternatively, the desired cDNA can be obtained

without using PCR by preparing or synthesizing a probe on the basis of the nucleotide sequence of hBSSP6 or mBSSP6 gene and screening a cDNA library directly. Among genes obtained by these methods, the gene of the present invention can be selected by confirming a nucleotide sequence thereof. The gene of the present invention can also be prepared according to a conventional method using chemical syntheses of nucleic acids, for example, phosphoramidite method (Mattencci, M. D. et al., J. Am. Chem. Soc., 130, 3185, 1981) and the like.

[0021]

In general, many genes of eucaryote exhibit polymorphism and, sometimes, one or more amino acids are substituted by this phenomenon. Further, even in such case, sometimes, a protein maintains its activity. Then, the present invention includes a gene encoding a protein obtained by modifying a gene encoding the amino acid sequence represented by SEQ ID NO: 2 or 4, artificially, in so far as the protein has the characteristic function of the gene of the present invention. Further, the present invention includes a protein which is a modification of the amino acid sequence represented by SEQ ID NO: 2 or 4 in so far as the protein has the characteristics of the present invention. Modification is understood to include substitution, deletion, addition and/or insertion. In

particular, the present inventors have shown that, even when several amino acids are added to or deleted from the N-terminus amino acid of hBSSP6 or mBSSP6 mature protein represented by SEQ ID NO: 2 or 4, the resultant sequence
5 maintains its activity.

[0022]

That is, the present invention includes a protein comprising either amino acid sequence described in SEQ ID NOS: 2 or 4; or one of these amino acid sequences wherein
10 one to several amino acids have been substituted, deleted, added and/or inserted, and being belonging to serine protease family.

[0023]

Each codon for the desired amino acid itself has been
15 known and it can be selected freely. For example, codons can be determined according to a conventional manner by taking into consideration of frequency of use of codons in a host to be utilized (Grantham, R. et al., Nucleic Acids Res., 9, r43, 1989). Therefore, the present invention also
20 includes a nucleotide sequence appropriately modified by taking into consideration of degeneracy of a codon. Further, these nucleotide sequences can be modified by a site directed mutagenesis using a primer composed of a synthetic oligonucleotide encoding the desired modification
25 (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA., 81, 5662,

1984), or the like.

[0024]

Furthermore, the DNA of the present invention includes DNA which is hybridizable to either of nucleotide sequences described in SEQ ID NO: 1 or 3, or nucleotide sequences complementary to these nucleotide sequences in so far as the protein encoded by the nucleotide sequence has the same properties as those of hBSSP6 or mBSSP6 of the present invention. It is considered that many of sequences which are hybridizable to a given sequence under stringent conditions have a similar activity to that of a protein encoded by the given sequence. The stringent conditions according to the present invention includes, for example, incubation in a solution containing 5 x SSC, 5% Denhardt's solution (0.1% BSA, 0.1% Ficoll 1400, 0.1% PVP), 0.5% SDS and 20 µg/ml denatured salmon sperm DNA at 37°C overnight, followed by washing with 2 x SSC containing 0.1% SDS at room temperature. Instead of SSC, SSPE can be appropriately used.

20 [0025]

Probes for detecting a hBSSP6 or mBSSP6 gene can be designed based on either of nucleotide sequences described in SEQ ID NO: 1 or 3. Or, primers can be designed for amplifying DNA or RNA containing the nucleotide sequence. To design probes or primers is carried out routinely by a

25

person skilled in the art. An oligonucleotide having a designed nucleotide sequence can be synthesized chemically. And, when a suitable label is added to the oligonucleotide, the resultant oligonucleotide can be utilized in various hybridization assays. Or, it can be utilized in nucleic acid synthesis reactions such as PCR. An oligonucleotide to be utilized as a primer has, preferably, at least 10 bases, more preferably 15 to 50 bases in length. An oligonucleotide to be utilized as a probe has, preferably, 100 bases to full length.

[0026]

Moreover, it is possible to obtain a promoter region and an enhancer region of a hBSSP6 or mBSSP6 gene present in the genome based on the cDNA nucleotide sequence of hBSSP6 or mBSSP6 provided by the present invention. Specifically, these control regions can be obtained according to the same manner as described in JP 6-181767 A; J. Immunol., 155, 2477, 1995; Proc. Natl. Acad. Sci., USA, 92, 3561, 1995 and the like. The promoter region used herein means a DNA region which is present upstream from a transcription initiation site and controls expression of a gene. The enhancer region used herein means a DNA region which is present in an intron, a 5'-non-translated region or a 3'-non-translated region and enhances expression of a gene.

[0027]

The present invention also relates to a vector comprising the nucleotide sequence represented by SEQ ID NO: 1 or a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 2; the nucleotide sequence represented by SEQ ID NO: 3 or a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 4; or a nucleotide sequence similar to them. A nucleotide sequence similar to a give nucleotide sequence used herein means a nucleotide sequence which is hybridizable to the given nucleotide sequence or its complementary nucleotide sequence under the above-described stringent conditions and encodes a protein having the same properties as those of the protein encoded by the nucleotide sequence.

[0028]

The vector is not specifically limited in so far as it can express the protein of the present invention. Examples thereof include pBAD/His, pRSETA, pCDNA2.1, pTrcHis2A, pYES2, pBlueBac4.5, pCDNA3.1 and pSecTag2 manufacture by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by Pharmacia, PfastBAC1 manufactured by GIBCO and the like. Preferably, a protein expression vector (described in the specification

of a patent application entitled "Protein expression vector and its use" and filed by the same applicant on the same day) is used. This expression vector is constructed by using pCRII-TOPO vector described in the Examples hereinafter, or a commercially available expression vector, for example pSecTag2A vector or pSecTag2B vector (Invitrogen) and integrating a secretory signal nucleotide sequence suitable for expression of the protein of the present invention, in the 3' downstream side thereof, a Tag nucleotide sequence, a cleavable nucleotide sequence and a cloning site, into which a nucleotide sequence encoding a target protein can be inserted, in this order. More specifically, it is preferred to use trypsin signal as the secretory signal, a nucleotide sequence encoding polyhistidine as the Tag nucleotide sequence, and a nucleotide sequence encoding an amino acid sequence which is susceptible to enzyme-specific cleavage, i.e., a nucleotide sequence encoding the amino acid sequence of Asp-Asp-Asp-Asp-Lys (said amino acid sequence is recognized by enterokinase, and the recombinant fusion protein is cleaved at the C-terminus part thereof) as the cleavable nucleotide sequence.

[0029]

Furthermore, the present invention provides transformed cells having the nucleotide sequence of the

present invention in an expressible state by means of the above vector. Preferably, host cells to be used for the transformed cells of the present invention are animal cells and insect cells. However, host cells include any cells
5 (including those of microorganisms) which can express a nucleotide sequence encoding the desired protein in the expression vector of the present invention and can secrete extracellularly.

The animal cells and insect cells used herein include
10 cells derived from human being and cells derived from fly or silk worm. For example, there are CHO cell, COS cell, BHK cell, Vero cell, myeloma cell, HEK293 cell, HeLa cell, Jurkat cell, mouse L cell, mouse C127 cell, mouse FM3A cell, mouse fibroblast, osteoblast, cartilage cell, S2, Sf9, Sf21,
15 High Five™ (registered trade mark) cell and the like. The microorganisms used herein include *E. coli*, yeast or the like.

[0030]

The protein of the present invention as such can be
20 expressed as a recombinant fused protein so as to facilitate isolation, purification and recognition. The recombinant fused protein used herein means a protein expressed as an adduct wherein a suitable peptide chain are added to the N-terminus and/or C-terminus of the desired
25 protein expressed by a nucleotide sequence encoding the

desired protein. The recombinant protein used herein means that obtained by integrating a nucleotide sequence encoding the desired protein in the expression vector of the present invention and cut off an amino acid sequence which derived
5 from nucleic acids other than those encoding the desired protein from the expressed recombinant fused protein, and is substantially the same as the protein of the present invention.

[0031]

10 Introduction of the above vector into host cells can be carried out by, for example, transfection according to lipopolyamine method, DEAE-dextran method, Hanahan method, lipofectin method or calcium phosphate method, microinjection, eletroporation and the like.

15 As described above, the present invention also relates to a process for producing hBSSP6 or mBSSP6 comprising culturing cells transformed with the above nucleotide sequence of the present invention and collecting the produced hBSSP6 or mBSSP6. The culture of cells and
20 separation and purification of the protein can be carried out by a per se known method.

[0032]

The present invention also relates to an inhibitor of the novel serine protease of the present invention.
25 Screening of the inhibitor can be carried out according to

a per se known method such as comparing the enzyme activity upon bringing into contact with a candidate compound with that without contact with the candidate compound, or the like

5 [0033]

The present invention relates to a non-human transgenic animal whose expression level of hBSSP6 or mBSSP6 gene has been altered. The hBSSP6 or mBSSP6 gene used herein includes cDNA, genomic DNA or synthetic DNA
10 encoding hBSSP6 or mBSSP6. In addition, expression of a gene includes any steps of transcription and translation. The non-human transgenic animal of the present invention is useful for studies of functions or expression control of hBSSP6 or mBSSP6, elucidation of mechanisms of diseases in
15 which hBSSP6 or mBSSP6 is presumed to be involved, and development of disease model animals for screening and safety test of medicine.

In the present invention, expression of a gene can be modified artificially by mutagenizing at a part of several
20 important sites which control normal gene expression (enhancer, promoter, intron, etc.) such as deletion, substitution, addition and/or insertion to increase or decrease an expression level of the gene in comparison with its inherent expression level. This mutagenesis can be
25 carried out according to a known method to obtain the

transgenic animal.

[0034]

In a narrow sense, the transgenic animal means an animal wherein a foreign gene is artificially introduced into reproductive cells by gene recombinant techniques. In a broad sense, the transgenic animal includes an antisense transgenic animal the function of whose specific gene is inhibited by using antisense RNA, an animal whose specific gene is knocked out by using embryonic stem cells (ES cells), and an animal into which point mutation DNA is introduced, and the transgenic animal means an animal into which a foreign gene is stably introduced into a chromosome at an initial stage of ontogeny and the genetic character can be transmitted to the progeny.

The transgenic animal used herein should be understood in a broad sense and includes any vertebrates other than a human being. The transgenic animal of the present invention is useful for studies of functions or expression control of hBSSP6 or mBSSP6, elucidation of mechanisms of diseases associated with cells expressing in a human being, and development of disease model animals for screening and safety test of medicine.

As a technique for creating the transgenic animal, a gene is introduced into a nucleus in a pronucleus stage of egg cells with a micropipette directly under a phase-

contrast microscope (microinjection, U.S. Patent 4,873,191).

Further, there are a method using embryonic stem cell (ES cell), and the like. In addition, there are newly

developed methods such as a method wherein a gene is

5 introduced into a retroviral vector or adenoviral vector to infect egg cells, a sperm vector method wherein a gene is introduced into egg cells through sperms, and the like.

A sperm vector method is a gene recombinant technique wherein a foreign gene is incorporated into sperm cells by
10 adhesion, electroporation, etc., followed by fertilization of egg cells to introduce the foreign gene into the egg cells (M. Lavitrano et al., Cell, 57, 717, 1989).

Alternatively, an in vivo site specific gene recombinant technique such as that using cre/loxP recombinase system of
15 bacteriophage P1, FLP recombinase system of *Saccharomyces cerevisiae*, etc. can be used. Furthermore, introduction of a transgene of the desired protein into a non-human animal using a retroviral vector has been reported.

[0036]

20 For example, a method for creating a transgenic animal by microinjection can be carried out as follows.

First, a transgene primarily composed of a promoter responsible for expression control, a gene encoding a specific protein and a poly A signal is required. It is
25 necessary to confirm expression modes and amounts between

respective systems because an expression mode and amount of a specific molecule is influenced by a promoter activity, and transgenic animals differ from each other according to a particular system due to the difference in a copy number of an introduced transgene and a introduction site on a chromosome. An intron sequence which is spliced may be previously introduced before the poly A signal because it has been found that an expression amount varies due to a non-translation region and splicing. Purity of a gene to be used for introduction into fertilized egg cells should be as high as possible. This is of importance. Animals to be used include mice for collecting fertilized eggs (5- to 6-week-old), male mice for mating, false pregnancy female mice, seminiferous tubule-ligated mice, and the like.

[0037]

For obtaining fertilized egg cells efficiently, ovulation may be induced with gonadotropin or the like. Fertilized egg cells are recovered and a gene in an injection pipette is injected into male pronucleus of the egg cells by microinjection. For returning the injected egg cells to a fallopian tube, an animal (false pregnancy female mouse, etc.) is provided and about 10 to 15 eggs/mouse are transplanted. Then, genomic DNA is extracted from the end part of the tail to confirm whether the transgene is introduced into newborn mouse or not.

This confirmation can be carried out by detection of the transgene with southern blot technique or PCR technique, or by positive cloning wherein a marker gene, which is activated only when homologous recombination is caused, has been introduced. Further, transcribed products derived from the transgene are detected by northern blot technique or RT-PCR technique to confirm expression of the transgene. Or, western blotting can be carried out with a specific antibody to a protein.

10 [0038]

The knockout mouse of the present invention is treated so that the function of mBSSP6 gene is lost. A knockout mouse means a transgenic mouse any of whose gene is destroyed by homologous recombination technique so that its function is deficient. A knockout mouse can be created by carrying out homologous recombination with ES cells and selecting embryonic stem cells wherein either of allele genes are modified or destroyed. For example, embryonic stem cells whose genes are manipulated at blastocyte or morula stage of fertilized eggs are injected to obtain a chimera mouse wherein cells derived from the embryonic stem cells are mixed with those derived from the embryo. The chimera mouse (chimera means a single individual formed by somatic cells based on two or more fertilized eggs) can be mated with a normal mouse to create a heterozygote mouse

15
20
25

wherein all of either of the allele genes have been modified or destroyed. Further, a homozygote mouse can be created by mating heterozygote mice.

[0039]

5 Homologous recombination means recombination between two genes whose nucleotide sequences are the same or very similar to each other in terms of gene recombination mechanism. PCR can be employed to select homologous recombinant cells. A PCR reaction can be carried out by
10 using a part of a gene to be inserted and a part of a region where the insertion is expected as primers to find out occurrence of homologous recombination in cells which give an amplification product. Further, for causing homologous recombination in a gene expressed in embryonic
15 stem cells, homologous recombinant cells can readily be selected by using a known method or its modification. For example, cells can be selected by joining a neomycin resistant gene to a gene to be introduced to impart neomycin resistance to cells after introduction.

20 [0040]

The present invention also provide an antibody recognizing hBSSP6 or mBSSP6 or a fragment thereof. The antibody of the present invention includes an antibody against a protein having the amino acid sequence described
25 in SEQ ID NO: 2 or 4 or its fragment. An antibody against

hBSSP6 or mBSSP6 or a fragment thereof (e.g., polyclonal antibody, monoclonal antibody, peptide antibody) or an antiserum can be produced by using hBSSP6 or mBSSP6 or a fragment thereof, etc. as an antigen according to a per se known process for producing an antibody or an antiserum.

[0041]

The hBSSP6 or mBSSP6 or a fragment thereof is administered to a site of a warm-blooded animal where an antibody can be produced by administration thereof as such or together with a diluent or carrier. For enhancing the antibody production, upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant may be administered. Normally, the administration is carried out once every 1 to 6 weeks, 2 to 10 times in all. Examples of the warm-blooded to be used include monkey, rabbit, dog, guinea pig, mouse, rat, sheep, goat, chicken and the like with mouse and rat being preferred. As rats, for example, Wistar and SD rats are preferred. As mice, for example, BALB/c, C57BL/6 and ICR mice are preferred.

[0042]

For producing monoclonal antibody producer cells, individuals whose antibody titer have been recognized are selected from warm-blooded animals, e.g., a mouse immunized with an antigen. Two to 5 days after the last immunization, the spleen or lymph node of the immunized animal is

collected and antibody producer cells contained therein are subjected to cell fusion with myeloma cells to prepare a monoclonal antibody producer hybridoma. The antibody titer in an antiserum can be determined by, for example, reacting
5 the antiserum with a labeled hBSSP6 or mBSSP6 as described hereinafter, followed by measurement of the activity bound to the antibody. The cell fusion can be carried out according to a known method, for example, that described by Koehler and Milstein (Nature, 256, 495, 1975) or its
10 modifications (J. Immunol. Method, 39, 285, 1980; Eur. J. biochem, 118, 437, 1981; Nature, 285, 446, 1980). As a fusion promoting agent, there are polyethylene glycol (PEG), Sendai virus and the like. Preferably, PEG is used. Further, for improving fusion efficiency, lectin, poly-L-
15 lysine or DMSO can be appropriately added.

[0043]

Examples of myeloma cells include X-63Ag8, NS-1, P3U1, SP2/0, AP-1 and the like with SP2/0 being preferred. The preferred ratio of the number of the antibody producer
20 cells (spleen cells) : the number of myeloma cells are 1 : 20 to 20 : 1. PEG (preferably PEG 1000 to PEG 6000) is added at a concentration of about 10 to 80% and the mixture is incubated at 20 to 40°C, preferably 30 to 37°C for 1 to 10 minutes to carry out the cell fusion efficiently.
25 Screening of anti-hBSSP6 or mBSSP6 antibody producer

hybridomas can be carried out by various methods. For example, a supernatant of a hybridoma culture is added to a solid phase to which hBSSP6 or mBSSP6 antigen is adsorbed directly or together with a carrier (e.g., microplate), followed by addition of an anti-immunoglobulin antibody (in case that the cells used in cell fusion is those of a mouse, anti-mouse immunoglobulin antibody is used) or protein A to detect the anti-hBSSP6 or mBSSP6 monoclonal antibody attached to the solid phase. Or, a supernatant of a hybridoma culture is added to a solid phase to which an anti-immunoglobulin antibody or protein A is adsorbed, followed by addition of hBSSP6 or mBSSP6 labeled with a radioactive substance, an enzyme, etc., to detect the anti-hBSSP6 or mBSSP6 monoclonal antibody attached to the solid phase.

[0044]

Selection and cloning of the anti-hBSSP6 or mBSSP6 monoclonal antibody can be carried out according to a per se known method or its modification. Normally, a HAT (hypoxanthine, aminopterin, thymidine)-added medium for culturing animal cells is used. Any culture medium can be used for selection, cloning and growing up in so far as the hybridoma can grow. For example, there can be used RPMI culture medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, or a serum-free medium for culturing

hybridomas. Preferably, the culture is carried out at a temperature of about 37°C. Normally, the culture time is 5 days to 3 weeks, preferably 1 weeks to 2 weeks. Normally, the culture is carried out under 5% CO₂. The antibody
5 titer of a supernatant of a hybridoma culture can be measured according to the same manner as that of the above-described measurement of anti-BSSP6 antibody titer in an antiserum. That is, examples of the measurement to be used include radioimmunoassay (RIA), enzyme-linked immunosorbent
10 assay (ELISA), FIA (fluorescence immunoassay), plaque assay, agglutination reaction method, and the like. Among them, ELISA as shown blew is preferred.

[0045]

Screening by ELISA

15 A protein prepared according to the same operation as that for an immunogen is immobilized on the surface of each well of an ELISA plate. Next, BSA, MSA, OVA, KLH, gelatin, skimmed milk, or the like is immobilized on each well to prevent non-specific adsorption. A supernatant of a
20 hybridoma culture is added to each well and is allowed to stand for a given time so that an immunological reaction proceeds. Each well is washed with a washing solution such as PBS or the like. Preferably, a surfactant is added to this washing solution. An enzyme labeled secondary
25 antibody is added and allowed to stand for a given time.

As the enzyme to be used for the label, there can be used β -galactosidase, alkaline phosphatase, peroxidase and the like. After washing each well with the same washing solution, a substrate solution of the labeled enzyme used
5 is added so that an enzymatic reaction proceeds.

When the desired antibody is present in the supernatant of a hybridoma culture, the enzymatic reaction proceeds and the color of the substrate solution is changed.

[0046]

10 Normally, cloning is carried out by a per se known method such as semi-solid agar method, limiting dilution method and the like. Specifically, after confirming a well in which the desired antibody is produced by the above-described method, cloning is carried out to obtain a single
15 clone. For cloning, it is preferred to employ limiting dilution method wherein hybridoma cells are diluted so that one colony is formed per one well of a culture plate. For cloning by limiting dilution method, feeder cells can be used, or a cell growth factor such as interleukin 6, etc.
20 can be added to improve colony forming capability. In addition, cloning can be carried out by using FACS and single cell manipulation method. The cloned hybridoma is preferably cultured in a serum-free culture medium and an optimal amount of an antibody is added to its supernatant.
25 The single hybridoma thus obtained can be cultured in a

large amount by using a flask or a cell culture device, or cultured in the abdominal cavity of an animal (J. Immunol. Meth., 53, 313, 1982) to obtain a monoclonal antibody. When culturing in a flask, there can be used a cell culture medium (e.g., IMDM, DMEM, RPMI1640, etc.) containing 0 to 20% of FCS. When culturing in the abdominal cavity of an animal, the animal to be used is preferably the same species or the same line as that from which the myeloma cells used in the cell fusion are derived, a thymus deficient nude mouse or the like, and the hybridoma is transplanted after administration of a mineral oil such as pristane, etc. After 1 to 2 weeks, myeloma cells are proliferated in the abdominal cavity to obtain ascites containing a monoclonal antibody.

[0047]

The monoclonal antibody of the present invention which does not cross-react with other proteins can be obtained by selecting a monoclonal antibody which recognizes an epitope specific to hBSSP6 or mBSSP6. In general, an epitope presented by an amino acid sequence composed of at least 3, preferably 7 to 20 successive amino acid residues in an amino acid sequence which constitutes a particular protein is said to be an inherent epitope of the protein. Then, a monoclonal antibody recognizing an epitope constituted by a peptide having an amino acid sequence composed of at least

3 successive amino acid residue selected from the amino
acid residues disclosed in either of SEQ ID NOS: 2, 4 and 6
can be said to be the monoclonal antibody specific for
hBSSP6 or mBSSP6 of the present invention. An epitope
5 common to BSSP6 family can be selected by selecting an
amino acid sequence conservative among the amino acid
sequences described in SEQ ID NOS: 2 and 4. Or, in case of
a region containing an amino acid sequence specific for
each sequence, a monoclonal antibody which can
10 differentiate respective proteins can be selected.

[0048]

Separation and purification of the anti-hBSSP6 or
mBSSP6 monoclonal antibody, like a conventional polyclonal
antibody, can be carried out according to the same manner
15 as those of immunoglobulins. As a known purification
method, there can be used a technique, for example, salting
out, alcohol precipitation, isoelectric precipitation,
electrophoresis, ammonium sulfate precipitation, absorption
and desorption with an ion exchange material (e.g., DEAE),
20 ultrafiltration, gel filtration, or specific purification
by collecting only an antibody with an antibody-binding
solid phase or an active adsorber such as protein A or
protein G, etc., and dissociating the binding to obtain the
antibody. For preventing formation of aggregates during
25 purification or decrease in the antibody titer, for example,

human serum albumin is added at a concentration of 0.05 to 2%. Alternatively, amino acids such as glycine, α -alanine, etc., in particular, basic amino acids such as lysine, arginine, histidine, etc., saccharides such as glucose, mannitol, etc., or salts such as sodium chloride, etc. can be added. In case of IgM antibody, since it is very liable to be aggregated, it may be treated with β -propionilactone and acetic anhydride.

[0049]

10 The polyclonal antibody of the present invention can be produced according to a per se known method or its modification. For example, an immunogen (protein antigen) per se or a complex thereof with a carrier protein is prepared and, according to the same manner as that in the
15 above monoclonal antibody production, a warm-blooded animal is immunized. A material containing an antibody against the protein of the present invention or its fragment is collected from the immunized animal and the antibody is separated and purified to obtain the desired antibody. As
20 for a complex of an immunogen and a carrier protein for immunizing a warm-blooded animal, the kind of a carrier protein and the mixing ratio of a carrier and a hapten are not specifically limited in so far as an antibody against the hapten immunized by cross-linking with the carrier is
25 efficiently produced. For example, there can be used about

0.1 to 20, preferably about 1 to 5 parts by weight of bovine serum albumin, bovine cycloglobulin, hemocyanin, etc. coupled with one part by weight of a hapten. For coupling a carrier and a hapten, various condensing agents can be used. Examples thereof include glutaraldehyde, carbodiimide or maleimide active ester, active ester agents having thiol group or dithiopyridyl group, and the like. The condensed product is administered as such or together with a carrier or diluent to a site of a warm-blooded animal where an antibody can be produced. For enhancing the antibody production, upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant may be administered. Normally, the administration is carried out once every 2 to 6 weeks, 3 to 10 times in all. The polyclonal antibody can be collected from blood, ascites, or the like, preferably blood of the immunized animal. The polyclonal antibody titer in an antiserum can be measured according to the same manner as measurement of the above monoclonal antibody titer in the antiserum. Separation and purification of the polyclonal antibody, like the above monoclonal antibody, can be carried out according to the same manner as those of immunoglobulins.

[0050]

The monoclonal antibody and polyclonal antibody against hBSSP6 or mBSSP6 or a fragment thereof can be

utilized for diagnosis and treatment of diseases associated with cells expressing hBSSP6 or mBSSP6. By using these antibodies, hBSSP6 or mBSSP6 or a fragment thereof can be determined based on their immunological binding to hBSSP6 or mBSSP6 or a fragment thereof of the present invention. Specifically, examples of a method for determining hBSSP6 or mBSSP6 or a fragment thereof by using these antibodies include a sandwich method wherein the antibody attached to an insoluble carrier and the labeled antibody are reacted with hBSSP6 or mBSSP6 or a fragment thereof to form a sandwich complex and the sandwich complex is detected, as well as a competitive method wherein labeled hBSSP6 or mBSSP6, and hBSSP6 or mBSSP6 or a fragment thereof in the specimen are competitively reacted with the antibody and hBSSP6 or mBSSP6 or a fragment thereof in the specimen is determined based on the amount of the labeled antigen reacted with the antibody.

[0051]

As a sandwich method for determining hBSSP6 or mBSSP6 or a fragment thereof, there can be used two step method, one step method and the like. In two step method, first, the immobilized antibody is reacted with hBSSP6 or mBSSP6 or a fragment thereof and then unreacted materials are completely removed by washing, followed by addition of the labeled antibody to form immobilized antibody-hBSSP6 or

mBSSP6-labeled antibody. In one step method, the immobilized antibody, labeled antibody and hBSSP6 or mBSSP6 or a fragment thereof are added at the same time.

[0052]

5 Examples of an insoluble carrier used for the determination include synthetic resins such as polystyrene, polyethylene, polypropylene, polyvinyl chloride, polyester, polyacrylate, nylon, polyacetal, fluorine plastic, etc.; polysaccharides such as cellulose, agarose, etc.; glass;
10 metal; and the like. An insoluble carrier may be shaped in various forms, for example, tray, sphere, fiber, rod plate, container, cell, test tube, and the like. The antibody adsorbed by a carrier is stored at a cold place in the presence of an appropriate preservative such as sodium
15 azide or the like.

[0053]

For immobilization of the antibody, a known chemical bonding method or a physical adsorption can be used. Examples of a chemical bonding method include a method
20 using glutaraldehyde; maleimide method using N-succusinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, N-succusinimidyl-2-maleimide acetate or the like; carbodiimide method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; or the like.
25 In addition, there are maleimidobenzoyl-N-

hydroxysuccinimide ester method, N-succinimidyl-3-(2-pyridylthio)propionic acid method, bisdiazobenzidine method, and dipalmityllysine method. Or, it is possible to capture a complex formed beforehand by reacting a material to be tested with two antibodies, whose epitopes are different, with an immobilized 3rd antibody against the antibody.

[0054]

For labeling, it is preferred to use enzyme, fluorescent substance, luminous substance, radioactive substance, metal chelate, or the like. Examples of the enzyme include peroxidase, alkaline phosphatase, β -D-galactosidase, malate dehydrogenase, *Staphylococcus* nuclease, δ -5-steroidisomerase, α -glycerol phosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, asparaginase, glucose oxidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase and the like. Examples of the fluorescent substance include fluorescein isothiocyanate, phycobiliprotein, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde, and the like. Examples of the luminous substance include isoluminol, lucigenin, luminol, aromatic acridinium ester, imidazole, acridinium salt and its modified ester, luciferin, luciferase, aequorin and the like. Examples of the radioactive substance include ^{125}I , ^{127}I , ^{131}I , ^{14}C , ^3H , ^{32}P , ^{35}S

and the like. The labeling material is not limited to them and any material which can be used for immunological determination can be used. Further, a low molecular weight hapten such as biotin, dinitrophenyl, pyridoxal or fluorescamine may be attached to the antibody. Preferably, horseradish peroxidase is used as a labeling enzyme. This enzyme can be reacted with various substrates and can readily be attached to the antibody by periodate method.

[0055]

10 When an enzyme is used as a labeling material, a substrate and, if necessary, a coloring enzyme is used for measuring its activity. In case of using peroxidase as the enzyme, H_2O_2 is used as a substrate and, as a coloring agent, there can be used 2,2'-azino-di-[3-ethylbenzthiazoline sulfonic acid] ammonium salt (ABTS),
15 5'-aminosalicylic acid, o-phenylenediamine, 4-aminoantipyrine, 3,3',5,5'-tetramethylbenzidine and the like. In case of using alkaline phosphatase as the enzyme, o-nitrophenylphosphate, p-nitrophenylphosphoric acid, or
20 the like can be used as a substrate. In case of using β -D-galactosidase as the enzyme, fluorescein-d-(β -D-galactopyranoside), 4-methylumbelliphenyl- β -D-galactopyranoside, or the like can be used as a substrate. The present invention also include a kit comprising the
25 above monoclonal antibody, polyclonal antibody and reagents.

[0056]

As a cross-linking agent, a known cross-linking agent such as N,N'-o-phenylenedimaleimide, 4-(N-maleimidomethyl)cyclohexanoate N-succinimide ester, 6-maleimidohexanoate N-succineimide ester, 4,4'-dithiopyridine or the like can be utilized. The reaction of these cross-linking agents with enzymes and antibodies can be carried out by a known method according to properties of a particular cross-linking agent. Further, as the antibody, a fragment thereof, for example, Fab', Fab, F(b'2) can be used as the case may be. A labeled enzyme can be obtained by the same treatment regardless of whether the antibody is polyclonal or monoclonal. When the above labeled enzyme obtained by using a cross-linking agent is purified by a known method such as affinity chromatography or the like, a immunoassay system having more higher sensitivity can be obtained. The enzyme labeled and purified antibody is stored at a dark cold place with addition of a stabilizer such as thimerosal, glycerin or after lyophilization.

An objective to be determined is not specifically limited in so far as it is a sample containing hBSSP6 or mBSSP6 or a fragment thereof, or a sample containing a precursor or a fragment thereof and includes body fluids such as plasma, serum, blood, serum, urine, tissue fluid,

cerebrospinal fluid and the like.

[0057]

The term "pro part" used herein means a part of a pro-form, i.e., the pro-form from which the corresponding active type protein part is removed. The term "pre part" used herein means a part of a prepro-form, i.e., the prepro-form from which the corresponding pro-form is removed. The term "prepro part" used herein means a part of a prepro-form, i.e., the prepro-form from which the corresponding active type protein part is removed.

[0058]

The amino acid sequence represented by SEQ ID NO: 2 (the 1st to 229th amino acids) is the hBSSP6 mature or active type protein composed of 229 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 687 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus in the amino acid sequence of the mature type protein of the present invention is deleted or added, while the above amino acid sequence is preferred.

[0059]

The amino acid sequence represented by SEQ ID NO: 2 (the -70th to 229th amino acids) is the hBSSP6 prostate type protein composed of 299 amino acids, and the

nucleotide sequence encoding the amino acid sequence is composed of 897 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus in the amino acid sequence of the prostate type protein is deleted or added, while the above amino acid sequence is preferred. The -70th to -1st amino acids is the prepro or pro part and this is considered to be a precursor type of hBSSP6 protein.

[0060]

The amino acid sequence represented by SEQ ID NO: 2 (the -21st to 229th amino acids) is the hBSSP6 brain type protein composed of 250 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 750 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus in the amino acid sequence of the brain type protein is deleted or added, while the above amino acid sequence is preferred. The -21st to -1st amino acids is the prepro or pro part and this is considered to be a precursor type of hBSSP6 protein.

[0061]

The amino acid sequence represented by SEQ ID NO: 4 (the 1st to 229th amino acids) is the mBSSP6 mature or active type protein composed of 229 amino acids, and the nucleotide sequence encoding the amino acid sequence is

composed of 687 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus in the amino acid sequence of the mature type protein is deleted or
5 added, while the above amino acid sequence is preferred.

[0062]

The amino acid sequence represented by SEQ ID NO: 4 (the -20th to 229th amino acids) is the mBSSP6 brain type protein composed of 249 amino acids, and the nucleotide
10 sequence encoding the amino acid sequence is composed of 747 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus in the amino acid sequence of the brain type protein is deleted or added,
15 while the above amino acid sequence is preferred. The -20th to -1st amino acids is the prepro or pro part and this is considered to be a precursor type of mBSSP6 protein.

[0063]

The amino acid sequence represented by SEQ ID NO: 4 (the -47th to 229th amino acids) is the mBSSP6 prostate
20 type protein composed of 276 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 828 bases. The present inventors have shown that the serine protease activity is maintained even when
25 one to several amino acids of the N-terminus in the amino

acid sequence of the prostate type protein is deleted or added, while the above amino acid sequence is preferred. The -47th to -1st amino acids is the prepro or pro part and this is considered to be a precursor type of mBSSP6 protein.

5 [0064]

EXAMPLES

Example 1

Cloning of novel serine proteases

The cloning was carried out by PCR using a human brain
10 cDNA library (Clontech) as the template and nucleotide sequences corresponding to an amino acid sequence common to serine proteases represented by

Primer 1: GTG CTC ACN GCN GCB CAY TG

Primer 2: CCV CTR WSD CCN CCN GGC GA

15 as the primers. Namely, 5 µl of the template, 5 µl of 10 x ExTaq buffer, 5 µl of dNTP, 10 pmol of each of the above primers and 0.5 µl of ExTaq (TAKARA) were added and the total volume was adjusted to 50 µl with sterilized water. PCR was carried out by repeating a cycle of heating at 94°C
20 for 0.5 minute, at 55°C for 0.5 minute and then at 72°C for 1 minutes, 35 times. The PCR product was mixed with pCR II-TOPO vector attached to TOPO TA cloning kit (Invitrogen) and the mixture was allowed to stand at room temperature for 5 minutes. Then, according to a conventional manner, *E.*
25 *coli* Top 10 attached to the kit was transformed and applied

to a LB (Amp⁺) plate. According to a conventional manner, a plasmid was extracted from each colony obtained and its nucleotide sequence was determined by cycle sequencing method with a fluorescence sequencer (ABI). Homology of the sequence of each clone was examined by means of GenBank. Regarding an unknown sequence, i.e., BSSP6 gene, the full length cDNA was obtained by 5' RACE and 3' RACE and, according to the same manner as described above, the nucleotide sequence was determined. As a result of northern blotting analysis thereof, intensive expression was observed in brain and prostate. Further, size of mRNA in brain differed from that in prostate. Then, primers specific for BSSP6 clone were prepared and PCR was carried out by using human brain Marathon-Ready cDNA (Clontech) and human prostate Marathon-Ready cDNA (Clontech), AP1 primer attached to this reagent and either of the above GSP1 primer and heating at 94°C for 2 minutes once and repeating a cycle of heating at 94°C for 30 seconds, at 60°C for 30 seconds and then at 72°C for 30 seconds 35 times. Then, 5 µl of the PCR product diluted to 1/100, 5 µl of 10 x buffer, 5 µl of dNTP, 10 pmol of either of 10 µM of the above GSP2 primer, 10 pmol of AP2 primer attached to the above reagent and 0.5 unit of ExTaq were admixed and adjusted to 50 µl with sterilized water. Then, according to the same manner as the above, PCR was carried out. The PCR product was

cloned by the above TOPO TA cloning kit and sequenced to obtain the upstream and downstream regions of the above clone. At this time, as for a clone which did not seem not to cover the full length of the protein, specific primers were prepared based on the newly founded sequence. Further, based on this sequence, the primers capable of amplifying ORF shown in Table 1 were prepared and PCR carried out using human brain Marathon-ready cDNA and human prostate Marathon-ready cDNA as a template to confirm that these clones were identical. This was cloned into pCR II-TOPO vector attached to TOPO TA cloning kit to obtain the plasmid pCR II/hBSSP6 containing the full length cDNA clone. According to the same manner, the plasmid pCRII/mBSSP6 containing a mouse homologous gene was obtained by carrying out 5' RACE and 3' RACE using mouse brain Marathon-Ready cDNA (Clontech) as a template, followed by cloning.

Table 1

Name of primer	Direc- tion	Sequence	Use
human BSSP6			
hBSSP6F1	Forward	TCAAGCCCCGCTACATAGTT	RACE
hBSSP6F2	Forward	ATCATGCTGGTGAAGATGGC	RACE
hBSSP6F3	Forward	GGACTCAAGAGAGGAACCTG	FL* (brain)
hBSSP6F4	Forward	ATCATCAAGGGGTTTCGAGTG	mature

hBSSP6F5	Forward	CTGCCTTGCTCCACACCTGG	FL* (pros.)
hBSSP6R1	Reverse	TTCTCACACTTCTGGTGCTC	RACE
hBSSP6R2	Reverse	ATGGTGTCTGTGATGTTGCC	RACE
hBSSP6R3/P	Reverse	AACTGCAGGAACCAAACACCAAGTGG	FL*

5 mousse BSSP6

mBSSP6F1	Forward	CGACTTCAACAACAGCCTCC	RACE
mBSSP6F2	Forward	CTTCTTTACCCGAGCTGTGC	RACE
mBSSP6F3	Forward	TAAGCTAGGAGAACTGAGGC	FL* (pros.)
mBSSP6F4	Forward	ATCAAGGGTTATGAGTGC	mature
mBSSP6F5	Forward	CTTACAGGCTTGGGGATTG	FL* (brain)
mBSSP6R1	Reverse	GATGATGCCTTGAAGAGATC	RACE
mBSSP6R2	Reverse	CATGGTGTCTGTGATGTTGCC	RACE
mBSSP6R3/E	Reverse	CGGAATTCGCATTAAGAAGAGGTTGGAG	FL*

*: for full length

15 [0066]

Example 2

Expression of hBSSP6 or mBSSP6 gene in human beings or mice internal organs

20 According to the protocol of QuickPrep Micro mRNA purification Kit (Amersham-Pharmacia), mRNAs were isolated from various internal organs of Balb/c mice or their fetuses and various tissues of human beings. They were subjected to electrophoresis according to a conventional manner and transcribed to a nylon membrane. A probe was

25 prepared separately by isolating a part of a nucleotide

sequence encoding the mature protein of mBSSP6 or the mature protein of hBSSP6 from pCR II/mBSSP6 or pCR II/hBSSP6, purifying it and labeling it with α -³²P dCTP. The probe was diluted with 5 x SSC and reacted with the

5 above membrane filter at 65°C overnight. According to the same manner, a probe was prepared by isolating a part of a nucleotide sequence encoding the mature protein of hBSSP6 from pCR II/hBSSP6, purifying it and labeling it with α -³²P dCTP. The probe was diluted with 5 x SSC and reacted with

10 human multiple tissue blot, human multiple blot II, human brain multiple tissue blot II or human brain multiple tissue blot IV (Clontech) membrane at 65°C overnight. Then, each membrane filter was washed twice each with 2 x SSC/0.1% SDS at room temperature for 30 minutes, 1 x

15 SSC/0.1% SDS at room temperature for 30 minutes and 0.1 x SSC/0.1% SDS at 65°C for 30 minutes. The filter was exposed to an imaging plate for FLA2000 (Fuji Film) for one day to analyze the expression. The results shown in the drawings are those obtained by using human multiple tissue

20 blot (clontech) membrane (Fig. 1), human multiple tissue blot II (Fig. 2), human brain multiple tissue blot II (Fig. 3), human brain multiple tissue blot IV (Fig. 4), mRNAs prepared from testicle, prostate and mucous gland (Fig. 5) as well as mRNAs prepared from brain of 15-day mouse

25 fetuses and brain of 12-day-old and 1-year-old mouse, and

mRNAs prepared from prostate, testicle and placenta of 3-month-old mice (Fig. 6). In addition, the mRNAs prepared above were subjected to RT-PCR of hBSSP6 or mBSSP6 by using Ready To Go RT-PCR Beads (Amersham-Pharmacia) and gene specific primers according to the protocol attached to the kit. As seen from Figs. 1 to 6, in case of northern blotting analysis, the expression of hBSSP6 was observed in each part of brain, placenta, lung, heart, testicle, prostate, mucous membrane gland and the like, and the expression of mBSSP6 was observed in brain of fetuses, prostate and testicle. Further, in case of RT-PCR, the expression of hBSSP6 was observed in hippocampus and prostate of adults. The expression of mBSSP6 was observed in brain and prostate of fetuses to grown up mice. Then, it is presumed that the novel serine proteases have various roles in placenta, lung, heart, testicle, prostate, mucous membrane gland and brain.

[0067]

Example 3

Determination of enzyme activity of novel serine protease mature protein encoded by hBSSP6 or mBSSP6 gene

(1) Construction of expression plasmid

A cDNA region encoding the mature protein of hBSSP6 or mBSSP6 protein was amplified by PCR using the plasmid pCR II/hBSSP6 or pCR II/mBSSP6 as a template. Each PCR product

was ligated to pTrc-HisB (Invitrogen) which had been digested with BamHI and blunted with mung bean nuclease according to a conventional method. *E. coli* JM109 was transformed by the resultant and colonies formed were
5 analyzed by PCR to obtain *E. coli* containing the desired serine protease expressing plasmid pTrcHis/hBSSP6 or pTrcHis/mBSSP6.

The resultant *E. coli* strains were designated *E. coli* pTrcHis/hBSSP6 and *E. coli* pTrcHis/mBSSP6 and deposited at
10 National Institute of Bioscience and Human-Technology (NIBH), Agency of Industrial Science & Technology on October 29, 1998 under the accession numbers of FERM P-17039 and FERM P-17036, respectively.

[0068]

15 (2) Expression of protein by *E. coli* containing expression plasmid

A single colony of *E. coli* having the expression plasmid was inoculated in 10 ml of LB (Amp⁺) culture medium and incubated at 37°C overnight. This was inoculated in
20 250 ml of LB (Amp⁺) culture medium and incubated at 37°C. When the absorbance at 600 nm became 0.5, 250 µl of 0.1 M IPTG (isopropyl-β-D-(-)-thiogalactopyranoside) was added and the incubation was continued for additional 5 hours. The *E. coli* was centrifuged and suspended in a cell
25 disruption buffer (10 mM phosphate buffer pH 7.5, 1 mM

EDTA) and sonicated on ice to disrupt *E. coli*. This was centrifuged at 14,000 r.p.m. at 4°C for 20 minutes to obtain a precipitate. The precipitate was washed twice with a cell disruption buffer containing 0.5% Triton X-100TM and washed with water to remove Triton X-100TM. Then, the resultant mixture was dissolved by soaking in a denaturation buffer containing 8 M urea (8M urea, 50 mM Tris pH8.5, 20 mM ME) at 37°C for 1 hour. The solution was passed through TALON metal affinity resin (Clontech), washed with the denaturation buffer containing 10 mM imidazole, and then eluted with the denaturation buffer containing 100 mM imidazole to purify the solution. The purified product was dialyzed against PBS for 3 days with exchanging the buffer every other night to obtain the protein hBSSP6-His or mBSSP6-His.

[0069]

Example 4

Expression of novel serine protease mature protein encoded by BSSP6 gene by using pFBTrypSigTag/BSSP6

(1) Construction of pFBTrypSigTag/BSSP6

The sequences represented by SEQ. ID NOS: 5 and 6 were subjected to annealing and digested with NheI and BamHI. The resultant fragment was inserted into NheI-BamHI digested pSecTag2A (Invitrogen) to obtain pSecTrypHis. Twenty units of BamHI was added to 5 µg of pSecTrypHis

vector and the vector was cleaved at 37°C over 4 hours. Then, 6 units of mung bean nuclease (TAKARA) was added thereto and reacted at room temperature (25°C) for 30 minutes to blunt the terminal ends. Further, the 3'-terminus side of the cloning site was cleaved with 20 units of XhoI, 1 unit of bacterial alkaline phosphatase (TAKARA) was added thereto and the reaction was carried out at 65°C for 30 minutes.

[0070]

According to the same manner as that described in JP 9-149790 A or Biochim. Biophys. Acta, 1350, 11, 1997, mRNA was prepared from COLO201 cells and cDNA was synthesized to obtain the plasmid pSPORT/neurosin. cDNA of an active region of neurosin was obtained from pSPORT/neurosin by PCR using primers having the sequences represented by SEQ ID NOS: 7 and 8. Ten units of XhoI was reacted with the PCR product at 37°C for 3 hours to cleave XhoI site at the 3'-side thereof. This was inserted into pSecTrypHis by TAKARA ligation kit to obtain pSecTrypHis/neurosin (Fig. 7).

[0071]

Amplification was carried out by using the primers having the sequences represented by SEQ ID NOS: 9 and 10 so that the peptide of Leu-Val-His-Gly was present at the C-terminus of the part from trypsin signal to the enterokinase recognition site of pSecTrypHis/neurosin.

This was inserted between NheI and HindIII sites of pSecTag2A to construct the plasmid pTrypSig. A sequence of about 200 bp containing His Tag region of pTrypHis was amplified by using primers having the sequence represented by SEQ ID NOS: 10 and 11 and a fragment of about 40 bp containing His Tag and enterokinase recognizing site formed by digestion of HindIII and BamHI was inserted into pTrypSig to construct pTrypSigTag (Fig. 8A).

[0072]

10 cDNA was prepared by PCR of the sequence from trypsin signal to enterokinase recognizing site of pTrypSigTag using primers having the sequences represented by SEQ ID NOS: 8 and 12 and cut out by digestion with BglII and BamHI. It was inserted into BamHI site of pFastBAC1. The
15 insertion direction was confirmed by PCR using primers having the sequences represented by SEQ ID NOS: 8 and 13. A clone into which the cDNA was inserted in the direction toward transcription and translation by polyhedrin promoter was selected to obtain pFBTrypSigTag.

20 [0073]

Twenty units of BamHI was added to 5 µg of pFBTrypSigTag vector and the vector was cleaved at 37°C over 4 hours, followed by addition of 6 units of mung bean nuclease (TAKARA) and reaction at room temperature (25°C)
25 for 30 minutes to blunt the terminal ends. Further, the

3'-side of the cloning site was cleaved by 20 units of EcoRI, followed by addition of 1 unit of bacterial alkaline phosphatase (TAKARA). The reaction was carried out at 65°C for 30 minutes.

5 [0074]

cdNA of the active region of hBSSP6 was obtained from pTrcHis/hBSSP6 prepared from E. coli pTrcHis/hBSSP6 (accession No. FERM P-17039) or pCRII/hBSSP6 by PCR according to a conventional manner using primers having the
10 sequences of SEQ ID NOS: 14 and 15. The resultant cdNA was inserted into pFBTrypSigTag to obtain pFBTrypSigTag/hBSSP6 (Fig. 7B). At this time, correct insertion of hBSSP6 was confirmed by determining the sequence using a fluorescence-labeled primer having the sequence of SEQ ID NO: 9. cdNA
15 of the active region of mBSSP6 is obtained from pTrcHis/mBSSP6 prepared from E. coli pTrcHis/mBSSP6 (FERM P-17036) or pCRII/mBSSP6. According to the same manner as described above, mBSSP6 can be expressed.

[0075]

20 Bacmid DNA was transformed with PFBTrypSigTag/hBSSP6 according to a protocol of Gibco BRL BAC-TO-BAC baculovirus expression system to prepare a recombinant bacmid having chimera hBSSP6 fused with trypsinogen signal peptide, His tag and enterokinase recognizing site. When this was
25 expressed in Sf-9 cell according to a manual of BAC-TO-BAC

baculovirus expression system, it was secreted in the culture supernatant from 2 days after infection of the virus.

[0076]

5 Determination of enzyme activity

The recombinant fused protein hBSSP6 obtained in the culture supernatant was passed through a chelate column to purify it and, after dialysis, its enzyme activity was determined. First, the culture supernatant was applied to
10 a chelate column (Ni-NTA-Agarose, Qiagen) with PBS buffer and eluted stepwise with a solution of imidazole (Wako Pure Chemical Industries, Ltd.) dissolved in PBS. The resultant imidazole-eluted fraction was applied to a PD-10 column (Pharmacia) to exchange to PBS buffer. Fifty μ l of this
15 sample was mixed with 10 μ l of enterokinase (1 U/1 μ l, Invitrogen) and the reaction was carried out at room temperature for 60 minutes. Each of various synthetic substrates (Peptide Laboratory) was dissolved in DMSO and diluted with 1 M Tris-HCl (pH 8.0) to obtain a substrate
20 solution. Fifty μ l of 0.2 M substrate solution was added thereto and further the reaction was carried out at 37°C. After one hour, the fluorescence of AMC (7-amino-4-methylcoumalin) formed by the enzymatic reaction was measured at 380 nm of excitation wavelength and 460 nm of
25 fluorescence wavelength to determine the activity (Fig. 9).

The value shown in the figure is that obtained by subtracting the fluorescence value of enterokinase alone from the measured value.

[SEQUENCE LISTING]

<110> Fuso Pharmaceutical Industries Ltd.

<120> Novel serine protease BSSP6

<130> 163447

5

<160> 15

<210> 1

<211> 1301

10

<212> DNA

<213> human

<400> 1

ctgccttgct ccacacctgg tcaggggaga gaggggagga aagccaaggg aaggaccta 60

15 actgaaaaca aacaagctgg gagaagcagg aatctgcgct cgggttccg 109

cag atg cag agg ttg agg tgg ctg cgg gac tgg aag tca tcg ggc aga ggt 160

Met Gln Arg Leu Arg Trp Leu Arg Asp Trp Lys Ser Ser Gly Arg Gly

-50

-45

-40

ctc aca gca gcc aag gaa cct ggg gcc cgc tcc tcc ccc ctc cag gcc atg 211

20 Leu Thr Ala Ala Lys Glu Pro Gly Ala Arg Ser Ser Pro Leu Gln Ala Met

-35

-30

-25

agg att ctg cag tta atc ctg ctt gct ctg gca aca ggg ctt gta ggg gga 262

Arg Ile Leu Gln Leu Ile Leu Leu Ala Leu Ala Thr Gly Leu Val Gly Gly

-20

-15

-10

-5

25 gag acc agg (atc atc aag ggg ttc gag tgc aag cct cac tcc cag ccc tgg 313

Glu Thr Arg Ile Ile Lys Gly Phe Glu Cys Lys Pro His Ser Gln Pro Trp
 -1 1 5 10
 cag gca gcc ctg ttc gag aag acg cgg cta ctc tgt ggg gcg acg ctc atc 364
 Gln Ala Ala Leu Phe Glu Lys Thr Arg Leu Leu Cys Gly Ala Thr Leu Ile
 5 15 20 25 30
 gcc ccc aga tgg ctc ctg aca gca gcc cac tgc ctc aag ccc cgc tac ata 415
 Ala Pro Arg Trp Leu Leu Thr Ala Ala His Cys Leu Lys Pro Arg Tyr Ile
 35 40 45
 gtt cac ctg ggg cag cac aac ctc cag aag gag gag ggc tgt gag cag acc 466
 10 Val His Leu Gly Gln His Asn Leu Gln Lys Glu Glu Gly Cys Glu Gln Thr
 50 55 60 65
 cgg aca gcc act gag tcc ttc ccc cac ccc ggc ttc aac aac agc ctc ccc 517
 Arg Thr Ala Thr Glu Ser Phe Pro His Pro Gly Phe Asn Asn Ser Leu Pro
 70 75 80
 15 aac aaa gac cac cgc aat gac atc atg ctg gtg aag atg gca tcg cca gtc 568
 Asn Lys Asp His Arg Asn Asp Ile Met Leu Val Lys Met Ala Ser Pro Val
 85 90 95
 tcc atc acc tgg gct gtg cga ccc ctc acc ctc tcc tca cgc tgt gtc act 619
 Ser Ile Thr Trp Ala Val Arg Pro Leu Thr Leu Ser Ser Arg Cys Val Thr
 20 100 105 110 115
 gct ggc acc agc tgc ctc att tcc ggc tgg ggc agc acg tcc agc ccc cag 670
 Ala Gly Thr Ser Cys Leu Ile Ser Gly Trp Gly Ser Thr Ser Ser Pro Gln
 120 125 130
 tta cgc ctg cct cac acc ttg cga tgc gcc aac atc acc atc att gag cac 721
 25 Leu Arg Leu Pro His Thr Leu Arg Cys Ala Asn Ile Thr Ile Ile Glu His

	135	140	145	150	
	cag aag tgt gag aac gcc tac ccc ggc aac atc aca gac acc atg gtg tgt	772			
	Gln Lys Cys Glu Asn Ala Tyr Pro Gly Asn Ile Thr Asp Thr Met Val Cys				
	155	160	165		
5	gcc agc gtg cag gaa ggg ggc aag gac tcc tgc cag ggt gac tcc ggg ggc	823			
	Ala Ser Val Gln Glu Gly Gly Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly				
	170	175	180		
	cct ctg gtc tgt aac cag tct ctt caa ggc att atc tcc tgg ggc cag gat	874			
	Pro Leu Val Cys Asn Gln Ser Leu Gln Gly Ile Ile Ser Trp Gly Gln Asp				
10	185	190	195	200	
	ccg tgt gcg atc acc cga aag cct ggt gtc tac acg aaa gtc tgc aaa tat	925			
	Pro Cys Ala Ile Thr Arg Lys Pro Gly Val Tyr Thr Lys Val Cys Lys Tyr				
	205	210	215		
	gtg gac tgg atc cag gag acg atg aag aac aat	tagactggac ccacccacca	978		
15	Val Asp Trp Ile Gln Glu Thr Met Lys Asn Asn				
	220	225			
	cagcccatca ccctccattt ccacttgggtg tttgggtcct gttcactctg ttaataagaa	1038			
	accctaagcc aagaccctct acgaacattc tttgggcctc ctggactaca ggagatgctg	1098			
	tcacttaata atcaacctgg gggtcgaaat cagtgaagacc tggattcaaa ttctgccttg	1158			
20	aaatattgtg actctgggaa tgacaacacc tggtttggtc tctgtgtat cccagcccc	1218			
	aaagacagct cctggccata tatcaagggt tcaataaata tttgctaaat gaaaaaaaaa	1278			
	aaaaaaaaa aaaaaaaaaa aaa	1301			
	<210> 2				
25	<211> 282				

<212> PRT

<213> human

<400> 2

5 Met Gln Arg Leu Arg Trp Leu Arg Asp Trp Lys Ser Ser Gly Arg Gly
 -50 -45 -40
 Leu Thr Ala Ala Lys Glu Pro Gly Ala Arg Ser Ser Pro Leu Gln Ala Met
 -35 -30 -25
 Arg Ile Leu Gln Leu Ile Leu Leu Ala Leu Ala Thr Gly Leu Val Gly Gly
 10 -20 -15 -10 -5
 Glu Thr Arg Ile Ile Lys Gly Phe Glu Cys Lys Pro His Ser Gln Pro Trp
 -1 1 5 10
 Gln Ala Ala Leu Phe Glu Lys Thr Arg Leu Leu Cys Gly Ala Thr Leu Ile
 15 20 25 30
 15 Ala Pro Arg Trp Leu Leu Thr Ala Ala His Cys Leu Lys Pro Arg Tyr Ile
 35 40 45
 Val His Leu Gly Gln His Asn Leu Gln Lys Glu Glu Gly Cys Glu Gln Thr
 50 55 60 65
 Arg Thr Ala Thr Glu Ser Phe Pro His Pro Gly Phe Asn Asn Ser Leu Pro
 20 70 75 80
 Asn Lys Asp His Arg Asn Asp Ile Met Leu Val Lys Met Ala Ser Pro Val
 85 90 95
 Ser Ile Thr Trp Ala Val Arg Pro Leu Thr Leu Ser Ser Arg Cys Val Thr
 100 105 110 115
 25 Ala Gly Thr Ser Cys Leu Ile Ser Gly Trp Gly Ser Thr Ser Ser Pro Gln

	120	125	130	
	Leu Arg Leu Pro His Thr Leu Arg Cys Ala Asn Ile Thr Ile Ile Glu His			
	135	140	145	150
	Gln Lys Cys Glu Asn Ala Tyr Pro Gly Asn Ile Thr Asp Thr Met Val Cys			
5	155	160	165	
	Ala Ser Val Gln Glu Gly Gly Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly			
	170	175	180	
	Pro Leu Val Cys Asn Gln Ser Leu Gln Gly Ile Ile Ser Trp Gly Gln Asp			
	185	190	195	200
10	Pro Cys Ala Ile Thr Arg Lys Pro Gly Val Tyr Thr Lys Val Cys Lys Tyr			
	205	210	215	
	Val Asp Trp Ile Gln Glu Thr Met Lys Asn Asn			
	220	225		
15	<210> 3			
	<211> 1323			
	<212> DNA			
	<213> mouse			
20	<400> 3			
	ccacatctga ctagggaagt aaggcgaagg aggcccatgg aagaaaaatc taaatgaaaa	60		
	cataagctag gagaactgag gcttcaaacc tgaagctatc ta atg agg agg ctg aag	117		
	Met Arg Arg Leu Lys			
	-45			
25	agt gac tgg aaa tta tct aca gaa acc agg gaa cct ggc gcc cgc cct gcc	168		

Ser Asp Trp Lys Leu Ser Thr Glu Thr Arg Glu Pro Gly Ala Arg Pro Ala
 -40 -35 -30
 cta ctc cag gcc agg atg att ctc cga ctc att gca ctt gct ctg gta aca 219
 Leu Leu Gln Ala Arg Met Ile Leu Arg Leu Ile Ala Leu Ala Leu Val Thr
 5 -25 -20 -15 -10
 ggg cac gta ggg gga gag acg agg atc atc aag ggt tat gag tgc agg cct 270
 Gly His Val Gly Gly Glu Thr Arg Ile Ile Lys Gly Tyr Glu Cys Arg Pro
 -5 -1 1 5
 cac tca cag cca tgg cag gtg gcc ctc ttt cag aag aca cgg ctt ctc tgt 321
 10 His Ser Gln Pro Trp Gln Val Ala Leu Phe Gln Lys Thr Arg Leu Leu Cys
 10 15 20 25
 ggg gca acc ctc atc gcc ccc aaa tgg ctc ctg aca gca gcc cac tgc cgc 372
 Gly Ala Thr Leu Ile Ala Pro Lys Trp Leu Leu Thr Ala Ala His Cys Arg
 30 35 40
 15 aag ccc cat tac gtg atc ctc ctt gga gag cac aat cta gag aag aca gac 423
 Lys Pro His Tyr Val Ile Leu Leu Gly Glu His Asn Leu Glu Lys Thr Asp
 45 50 55 60
 ggc tgt gag cag agg cgg atg gcc act gag tcc ttc ccc cac ccc gac ttc 474
 Gly Cys Glu Gln Arg Arg Met Ala Thr Glu Ser Phe Pro His Pro Asp Phe
 20 65 70 75
 aac aac agc ctc ccc aac aaa gac cac cgg aat gac ata atg ctt gtg aag 525
 Asn Asn Ser Leu Pro Asn Lys Asp His Arg Asn Asp Ile Met Leu Val Lys
 80 85 90
 atg tgc tct ccc gtc ttc ttt acc cga gct gtg cag cca ctc acc ctg tcc 576
 25 Met Ser Ser Pro Val Phe Phe Thr Arg Ala Val Gln Pro Leu Thr Leu Ser

	95	100	105	110	
	cca cac tgt gtc gct gca ggc acc agc tgc ctc att tct gga tgg ggc acc	627			
	Pro His Cys Val Ala Ala Gly Thr Ser Cys Leu Ile Ser Gly Trp Gly Thr				
	115	120	125		
5	acg tcc agc ccc cag ttg cgc ctg cct cat tcc ttg cga tgt gcc aat gtc	678			
	Thr Ser Ser Pro Gln Leu Arg Leu Pro His Ser Leu Arg Cys Ala Asn Val				
	130	135	140	145	
	tcc atc atc gaa cac aag gag tgt gag aag gcc tac ccg ggc aac atc aca	729			
	Ser Ile Ile Glu His Lys Glu Cys Glu Lys Ala Tyr Pro Gly Asn Ile Thr				
10	150	155	160		
	gac acc atg ctg tgc gcc agt gtt cgg aaa gag ggc aag gac tcc tgt cag	780			
	Asp Thr Met Leu Cys Ala Ser Val Arg Lys Glu Gly Lys Asp Ser Cys Gln				
	165	170	175		
	ggt gac tct gga ggc ccc ctg gtc tgc aac gga tct ctt caa ggc atc atc	831			
15	Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Ser Leu Gln Gly Ile Ile				
	180	185	190	195	
	tcc tgg ggt cag gac cca tgt gcc gtc acc aga aag cct ggt gtc tat aca	882			
	Ser Trp Gly Gln Asp Pro Cys Ala Val Thr Arg Lys Pro Gly Val Tyr Thr				
	200	205	210		
20	aaa gtc tgc aaa tac ttt aac tgg atc cac gag gtt atg agg aac aat	930			
	Lys Val Cys Lys Tyr Phe Asn Trp Ile His Glu Val Met Arg Asn Asn				
	215	220	225		
	tagaggggac ctgcttccca ccaccaacc cctccaacct cttcttaatg ctttgacttc	990			
	tcttcattct gccctaagaa gtcctcagct gggaccctgg catgtactct ctccgaccca	1050			
25	ccatgagtat agtatagga tgctctaact tgatgatcga cctggggcct ggaatcaaat	1110			

cctgacttga actaaattgt gactctggac atgatcacca ctggttttgt ttgtttggtt 1170
 gttttttgtt ttgttttgtt ttgttcccag ctttgaagac agtccctggc atatcccagg 1230
 gtttcaataa atatttgta aatgataaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1290
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1323

5

<210> 4

<211> 276

<212> PRT

<213> mouse

10

<400> 4

Met Arg Arg Leu Lys

-45

Ser Asp Trp Lys Leu Ser Thr Glu Thr Arg Glu Pro Gly Ala Arg Pro Ala

15

-40

-35

-30

Leu Leu Gln Ala Arg Met Ile Leu Arg Leu Ile Ala Leu Ala Leu Val Thr

-25

-20

-15

-10

Gly His Val Gly Gly Glu Thr Arg Ile Ile Lys Gly Tyr Glu Cys Arg Pro

-5

-1 1

5

20

His Ser Gln Pro Trp Gln Val Ala Leu Phe Gln Lys Thr Arg Leu Leu Cys

10

15

20

25

Gly Ala Thr Leu Ile Ala Pro Lys Trp Leu Leu Thr Ala Ala His Cys Arg

30

35

40

Lys Pro His Tyr Val Ile Leu Leu Gly Glu His Asn Leu Glu Lys Thr Asp

25

45

50

55

60

Gly Cys Glu Gln Arg Arg Met Ala Thr Glu Ser Phe Pro His Pro Asp Phe
 65 70 75
 Asn Asn Ser Leu Pro Asn Lys Asp His Arg Asn Asp Ile Met Leu Val Lys
 80 85 90
 5 Met Ser Ser Pro Val Phe Phe Thr Arg Ala Val Gln Pro Leu Thr Leu Ser
 95 100 105 110
 Pro His Cys Val Ala Ala Gly Thr Ser Cys Leu Ile Ser Gly Trp Gly Thr
 115 120 125
 Thr Ser Ser Pro Gln Leu Arg Leu Pro His Ser Leu Arg Cys Ala Asn Val
 10 130 135 140 145
 Ser Ile Ile Glu His Lys Glu Cys Glu Lys Ala Tyr Pro Gly Asn Ile Thr
 150 155 160
 Asp Thr Met Leu Cys Ala Ser Val Arg Lys Glu Gly Lys Asp Ser Cys Gln
 165 170 175
 15 Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Ser Leu Gln Gly Ile Ile
 180 185 190 195
 Ser Trp Gly Gln Asp Pro Cys Ala Val Thr Arg Lys Pro Gly Val Tyr Thr
 200 205 210
 Lys Val Cys Lys Tyr Phe Asn Trp Ile His Glu Val Met Arg Asn Asn
 20 215 220 225

<210> 5

<211> 99

<212> DNA

25 <213> Artificial Sequence

<220>

<223> Sequence for synthetic primer for amplification

<400> 5

5 AAG CTT GGC TAG CAA CAC CAT GAA TCT ACT CCT GAT CCT TAC CTT TGT TGC 51
TGC TGC TGT TGC TGC CCC CTT TGA CGA CGA TGA CAA GGA TCC GAA TTC 99

<210> 6

<211> 99

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

15 <400> 6

GAA TTC GGA TCC TTG TCA TCG TCG TCA AAG GGG GCA GCA ACA GCA GCA GCA 51
ACA AAG GTA AGG ATC AGG AGT AGA TTC ATG GTG TTG CTA GCC AAG CTT 99

<210> 7

20 <211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

25

<400> 7

TTG GTG CAT GGC GGA

15

<210> 8

5 <211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

10

<400> 8

TCC TCG AGA CTT GGC CTG AAT GGT TTT

27

<210> 9

15 <211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

20

<400> 9

GCG CTA GCA GAT CTC CAT GAA TCT ACT CCT GAT CC

35

<210> 10

25 <211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

5

<400> 10

TGA AGC TTG CCA TGG ACC AAC TTG TCA TC

29

<210> 11

10

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

15

<400> 11

CCA AGC TTC ACC ATC ACC ATC ACC AT

26

<210> 12

20

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

25

<400> 12

GCA CAG TCG AGG CTG AT

17

<210> 13

5 <211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

10

<400> 13

CAA ATG TGG TAT GGC TG

17

<210> 14

15 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

20

<400> 14

ATC ATC AAG GGT TAT GAG TG

20

<210> 15

25 <211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Sequence of synthetic primer for amplification

5

<400> 15

CGG AAT TCG CAT TAA GAA GAG GTT GGA G

28

Brief Description of the Drawings:

Fig. 1 illustrates the results of northern blotting using human multiple tissue blot membrane.

Fig. 2 illustrates the results of northern blotting using human multiple tissue blot II.

Fig. 3 illustrates the results of northern blotting using human brain multiple tissue blot II.

Fig. 4 illustrates the results of northern blotting using human brain multiple tissue blot IV.

Fig. 5 illustrates the results of northern blotting using mRNA prepared in Example 2.

Fig. 6 illustrates the results of northern blotting using mRNA prepared in Example 2.

Fig. 7 illustrates the plasmid constructed by the method of Example 4.

Fig. 8 illustrates the construction of plasmid according to the method of Example 4.

Fig. 9 illustrates the substrate specificity of hBSSP6.

Document Name: Abstract


Problem: To provide novel mouse and human serine proteases (BSSP6).


Solving Means: To provide proteins having the amino acid
5 sequences represented by SEQ ID NOS: 2, 4 and 6; proteins
having amino acid sequences derived from these amino acid
sequences by deletion, substitution or addition of one to
several amino acids; and nucleotide sequences encoding the
same; transgenic non-human animals with altered expression
10 level of a serine protease BSSP6; an antibody against
BSSP6; and a method for detecting BSSP6 in a specimen by
using the antibody.

Selected Figure: none

THIS PAGE BLANK (USPTO)

Fig. 1






THIS PAGE BLANK (USPTO)



Fig. 2

hBSSP-6






THIS PAGE BLANK (USPTO)



Fig. 3


hBSSP-6



THIS PAGE BLANK (USPTO)

Fig. 4

hBSSP-6






THIS PAGE BLANK (USPTO)

Fig. 5

hBSSP-6






THIS PAGE BLANK (USPTO)

Fig. 6


mBSSP-6






THIS PAGE BLANK (USPTO)


Fig. 7





THIS PAGE BLANK (USPTO)

Fig. 8







THIS PAGE BLANK (USPTO)



Fig. 9

substrate specificity of hBSSP6





THIS PAGE BLANK (USPTO)

(Translation)

RECEIPT OF MICROORGANISM DEPOSIT



Notice No.: No. 10, No. 1377

Notice Date: October 29, 1998

To: FUSO PHARMACEUTICAL INDUSTRIES, LTD.

Mikio TODA, Representative Director

National Institute of Bioscience and Human-Technology
Agency of Industrial Science and Technology
Shinichi OHASHI,
Ph. D., DIRECTOR GENERAL

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: E. coli pTrcHis/hBSSP6	Accession number given by the DEPOSITORY AUTHORITY: FERM P-17039
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation	
III. RECEIPT AND ACCEPTANCE	
This Depository Authority accepts the microorganism identified under I above, which was received by it on October 29, 1998.	



THIS PAGE BLANK (USPTO)

(Translation)

RECEIPT OF MICROORGANISM DEPOSIT



Notice No.: No. 10, No. 1374

Notice Date: October 29, 1998

To: FUSO PHARMACEUTICAL INDUSTRIES, LTD.

Mikio TODA, Representative Director

National Institute of Bioscience and Human-Technology

Agency of Industrial Science and Technology

Shinichi OHASHI,

Ph. D., DIRECTOR GENERAL

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR:

E. coli pTrcHis/mBSSP6

Accession number given by the
DEPOSITARY AUTHORITY:

FERM P-17036

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I above was accompanied by:

- ☒ a scientific description
- ☒ a proposed taxonomic designation

III. RECEIPT AND ACCEPTANCE

This Depository Authority accepts the microorganism identified under I above, which was received by it on October 29, 1998.



THIS PAGE BLANK (USPTO)